What is the Frontotemporal Dementia Market?


 

What is the Frontotemporal Dementia Market?

DelveInsight’s ‘Frontotemporal Dementia Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Frontotemporal dementia (FTD), historical and forecasted epidemiology as well as the Frontotemporal Dementia market trends in the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

What is the Frontotemporal Dementia Market Size Report?

The Frontotemporal Dementia market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM Frontotemporal Dementia market size from 2019 to 2032. The Report also covers current Frontotemporal Dementia treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

What are Frontotemporal Dementia and its treatment?

FTD is a term used to describe a group of neurocognitive disorders that encompass progressive dysfunction in executive functioning, behavior, and language. There are three types of frontotemporal disorders (FTD): behavioral variant frontotemporal dementia (bvFTD), primary progressive aphasia (PPA), and movement disorders. FTD occurs when brain cells in the frontal or temporal lobes die due to the build-up of abnormal proteins, leading to abnormal brain function, and more cell deaths result in brain atrophy. Many possible symptoms can result, including unusual behaviors, emotional problems, trouble communicating, difficulty with work, or difficulty with walking. FTD can be hard to diagnose as it displays clinical symptoms that can be mistaken for other dementias or psychiatric disorders. The average time from symptom onset to accurate diagnosis is about 3.6 years.

Diagnosis of FTD currently includes Imaging and blood or cerebrospinal fluid studies. A ‘definite’ diagnosis of FTD is still based on neuropathology confirmation postmortem. Diagnostic markers currently used for FTD include imaging and blood or cerebrospinal fluid studies. They may best serve a diagnostic role when used in a multimodal approach to achieve a ‘definite’ diagnosis of FTD in the living patient as soon as possible. The management of problematic behaviors in FTD with mainly sparse case reports and case series detailing their effectiveness lacks the study quality. The main purpose of nonpharmacological interventions—described below—is to prevent disruptive behaviors, provide symptom relief, and lessen caregiver distress.

What are the Frontotemporal Dementia Emerging Drugs? 

AL001: Alector

It is monoclonal antibody designed to modulate progranulin, a regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including FTD, Alzheimer’s disease, and Parkinson’s disease. Company has initiated phase III trial for FTD-GRN mutation and undergoing phase II trials for FTD-C9orf72 to test its safety and efficacy towards FTD. 

PBFT02: Passage Bio

It is a gene therapy that utilizes an AAV1 viral vector to deliver a modified DNA encoding the granulin (GRN) gene to a patients cells. The company has an active IND from the FDA and approved CTAs in multiple countries, which allows them to proceed with multi-center, open-label, single-arm Phase I/II clinical trial of PBFT02 in patients with a diagnosis of early symptomatic FTD-GRN.

What is the Frontotemporal Dementia Market Outlook?

Currently, there are no FDA, EMA or PMDA (Pharmaceuticals and Medical Devices Agency) approved disease-modifying therapies for the management of FTD. The current treatment strategies mainly rely upon the off-label use of medications for symptomatic management, and most therapies lack quality evidence from randomized, placebo-controlled clinical trials. The FTD drugs market is categorized based on drug class such as Selective serotonin reuptake inhibitors (Citalopram, Fluoxetine), Antipsychotic Agents, Cholinesterase Inhibitors (donepezil, rivastigmine, and galantamine), NMDA receptor antagonists (Memantine), and Benzodiazepine Antianxiety Drugs.

Frontotemporal Dementia Key Findings 

·         The Frontotemporal Dementia market size in seven major markets was USD 92 million in 2021, which is further expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 16% for the study period (2019–2032) 

·         The expected launch of potential therapy may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of Frontotemporal Dementia. 

·         Upcoming therapy such as AL001 has the potential to create a significant positive shift in the Frontotemporal Dementia market size. 

·         The United States accounts for the largest market size of Frontotemporal Dementia, in comparison to the EU5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.

Get to know more about the key players of the report @ Frontotemporal Dementia Market Companies


Trending Market Research Reports in 2023

  1. Lactose Intolerance Market
  2. Shingles Market
  3. Persistent Epithelial Defect Market
  4. Oncolytic Virus Cancer Therapy Pipeline
  5. Stem Cell Market
  6. Vital Sign Monitors Devices Market
  7. Radiation Retinopathy Market
  8. Pelizaeus-Merzbacher Disease Market
  9. Adult T-Cell Leukemia-Lymphoma Market
  10. Drug-Resistant Epilepsy Market
  11. Hypoxic Ischemic Encephalopathy Market
  12. Myopia Progression Market
  13. Ptosis Market
  14. Tay-Sachs Disease Market
  15. Cannabis Use Disorder Market
  16. Myocardial Infarction Market
  17. Diabetes Insipidus Market
  18. Kawasaki Disease Market
  19. Chagas Disease Market
  20. Glioblastoma Multiforme Market
  21. Polycystic Kidney Disease Market
  22. Uterine Leiomyoma (Uterine Fibroids) Market
  23. Meningococcal Meningitis Market
  24. Radiodermatitis Market
  25. Intraocular Lens Market


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Yash Bhardwaj

info@delveinsight.com


Comments

Post a Comment

Popular posts from this blog

Unveiling the Future of Prostate Cancer Treatment: Insights from DelveInsight

Image
  In the realm of oncology, prostate cancer stands as a significant challenge, affecting millions of men worldwide. Despite advancements in treatment modalities, a subset of patients face the daunting reality of castration-resistant prostate cancer (CRPC), where traditional therapies lose their efficacy. DelveInsight, a renowned market research firm, has delved into the intricacies of this landscape to provide invaluable insights into the market outlook. Understanding the Market Dynamics: DelveInsight's comprehensive analysis sheds light on the evolving dynamics of the castration-resistant prostate cancer market. By scrutinizing factors such as disease prevalence, treatment options, emerging therapies, and market trends, DelveInsight offers a nuanced understanding of this complex domain. Market Size and Growth: The prostate cancer therapeutics market, particularly in the castration-resistant segment, continues to witness substantial growth. With an aging population and advancements...
Read more

Navigating Healthcare Trends: Market Research Report on Emerging Opportunities

Image
  Von Hippel-Lindau Disease Market DelveInsight's Von Hippel-Lindau (VHL) Disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Von Hippel-Lindau (VHL) Disease Chronic   Rhinosinusitis   with   Nasal   Polyps  Market Chronic rhinosinusitis with nasal polyps Market report delivers an in-depth understanding of the Chronic rhinosinusitis with nasal polyps, historical and forecasted market trends in the 7MM Abdominal   Aortic   Aneurysm  Market DelveInsight's Abdominal Aortic Aneurysm Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Abdominal Aortic Aneurysm Acid   sphingomyelinase   deficiency  Market DelveInsight's Acid sphingomyelinase deficiency (ASMD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the ASMD market trends in 7MM. Acne   Vulgaris...
Read more

What are the key strengths of Macular Telangiectasia Market Report?

Image
  What is the Macular Telangiectasia? Macular telangiectasia (MacTel) is a disease that affects the macula, causing central vision loss. It’s caused by abnormal blood vessels around the fovea. The fovea is centre of the macula and is used for detailed central vision. There are two main types of macular telangiectasia – type 1 and type 2. The blood vessel changes are different in each type. What is the  Macular Telangiectasia Market ? DelveInsight's "Macular Telangiectasia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Macular Telangiectasia, historical and forecasted epidemiology as well as the Macular Telangiectasia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. What is the Macular Telangiectasia Market Report? The Macular Telangiectasia market report provides current treatment practices, emerging drugs, Macular Telangiectasia market share of the individual ...
Read more